Ferric Carboxymaltose (Ferinject)

Abstract

The Canada’s Drug Agency (CDA-AMC) Canadian Drug Expert Committee (CDEC) recommends that public drug programs reimburse Ferinject for the treatment of iron deficiency anemia if certain conditions are met. Ferinject should only be covered to treat patients with iron deficiency anemia who are aged 1 year or older when oral iron preparations are not tolerated or are ineffective according to the reimbursement criteria used for IV iron formulations that are currently reimbursed by public drug plans. CDEC noted that patients with underlying risk factors for hypophosphatemia may require monitoring of serum phosphate if they require multiple doses of ferric carboxymaltose for long-term treatment. Ferinject should only be reimbursed if it is prescribed by a clinician with expertise in managing iron deficiency anemia in adult and pediatric patients aged 1 year and older and the cost of Ferinject is reduced.